Psychedelic Therapy Trials Will Face Cash Strain Yet Could Unlock Long Term Upside

Catalysts

About Cybin

Cybin is a clinical stage biopharmaceutical company developing psychedelic based therapies for major depressive disorder and generalized anxiety disorder.

What are the underlying business or industry changes driving this perspective?

• Although CYB003 holds breakthrough therapy designation in major depressive disorder and has progressed into global Phase III trials with approximately 60 planned sites, the company still depends on clean execution across multiple geographies. Any delay or protocol issue could push out potential revenue timing and extend the period of elevated R&D expense and net losses.
• While the clinic focused model for short, staff light psychedelic sessions fits with the growing interventional psychiatry clinic infrastructure, real world adoption will depend on clinics consistently integrating CYB003 and CYB004 into existing workflows. This must be done without adding hidden staffing or training costs, which could pressure margins if payer reimbursement does not fully recognize the visit intensity.
• Although the financing completed after quarter end added US$175 million on top of US$83.8 million of cash, cash equivalents and investments and allowed retirement of the High Trail debt, the business remains loss making with quarterly cash based operating expenses of US$28.5 million. Any extension of trial timelines or expanded commercial build out could lead to further capital needs and ongoing dilution before earnings turn positive.
• While CYB004 intramuscular dosing is intended to support brief, predictable anxiety treatment sessions that align with current ketamine practices and may appeal to clinics, the Phase II study in only 36 patients is not powered as a pivotal trial. Weaker than hoped dose response or durability signals could slow movement into Phase III and delay any contribution to revenue or help to spread fixed commercial costs.
• Although long term maintenance concepts like efficient retreatment and extended follow up out to 12 months are built into both CYB003 and CYB004, actual retreatment frequency and durability will only be clear after more data from EXTEND and other long term work. If patients require more frequent sessions than assumed, that could weigh on payer acceptance and compress net margins even if top line revenue grows.

Assumptions

How have these above catalysts been quantified?

• This narrative explores a more pessimistic perspective on Cybin compared to the consensus, based on a Fair Value that aligns with the bearish cohort of analysts.
• Cybin currently has no revenue. The bearish analysts are forecasting revenue to reach $5.5 million by June 2029.
• The bearish analysts are not forecasting that Cybin will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Cybin's profit margin will increase from 0.0% to the average US Pharmaceuticals industry of 19.6% in 3 years.
• If Cybin's profit margin were to converge on the industry average, you could expect earnings to reach $1.1 million (and earnings per share of $0.02) by about June 2029, up from -$123.2 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $73.8 million in earnings, and the most bearish expecting $-249.5 million.
• In order for the above numbers to justify the price target of the more bearish analyst cohort, the company would need to trade at a PE ratio of 536.7x on those 2029 earnings, up from -2.4x today. This future PE is greater than the current PE for the US Pharmaceuticals industry at 15.4x.
• The bearish analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 6.92%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• Cybin remains a pre revenue company while reporting a net loss of US$33.7 million for the quarter and cash based operating expenses of US$28.5 million. If psychedelic based therapies take longer than expected to gain broad clinical and payer acceptance, the company may need additional capital, which could pressure earnings and dilute any eventual per share value.
• The investment case leans heavily on CYB003 and CYB004 progressing through late stage trials, yet both programs still depend on clean execution, long term durability data and regulatory approval. Any clinical setback, weaker than expected outcomes or regulatory delay could limit or postpone potential revenue and keep net margins under pressure for longer.
• The company is building a model around interventional psychiatry clinics that already use treatments like SPRAVATO and ketamine. If clinics are slow to adopt new protocols, struggle to integrate staff light workflows or if payers are cautious on reimbursing psychedelic sessions, utilization could fall short of expectations, weighing on both revenue and earnings.
• Cybin is preparing for global commercialization with approximately 60 planned sites for EMBRACE, manufacturing partnerships and commercial groundwork. The broader psychedelics sector still faces evolving social, regulatory and payer views, so any shift in sentiment or tighter controls on psychedelic medicines could constrain market size and compress long term revenue and margin potential.
• The company has strengthened its cash position with US$83.8 million of cash, cash equivalents and investments at quarter end and a subsequent US$175 million financing. Future trial extensions, additional long term studies like EXTEND and any commercial build out could increase cash needs, which may lead to further financings that weigh on per share earnings and limit upside from any eventual revenue ramp.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The assumed bearish price target for Cybin is $7.78, which represents up to two standard deviations below the consensus price target of $42.73. This valuation is based on what can be assumed as the expectations of Cybin's future earnings growth, profit margins and other risk factors from analysts on the more bearish end of the spectrum.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $91.14, and the most bearish reporting a price target of just $7.78.
• In order for you to agree with the more bearish analyst cohort, you'd need to believe that by 2029, revenues will be $5.5 million, earnings will come to $1.1 million, and it would be trading on a PE ratio of 536.7x, assuming you use a discount rate of 6.9%.
• Given the current share price of $6.02, the analyst price target of $7.78 is 22.7% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.